Purpose: Inherited retinal dystrophies (IRDs) represent a group of progressive conditions affecting the retina. There is a great genetic heterogeneity causing IRDs, and to date, more than 260 genes are associated with IRDs. Stargardt disease, type 1 (STGD1) or macular degeneration with flecks, STGD1 represents a disease with early onset, central visual impairment, frequent appearance of yellowish flecks and mutations in the ATP-binding cassette subfamily A, member 4 (ABCA4) gene. A large number of intronic sequence variants in ABCA4 have been considered pathogenic although their functional effect was seldom demonstrated. In this study, we aimed to reveal how intronic variants present in patients with Stargardt from the same Swedish family affect splicing. Methods: The splicing of the ABCA4 gene was studied in human embryonic kidney cells, HEK293T, and in human retinal pigment epithelium cells, ARPE-19, using a minigene system containing variants c.4773+3A>G and c.5461-10T>C. Results: We showed that both ABCA4 variants, c.4773+3A>G and c.5461-10T>C, cause aberrant splicing of the ABCA4 minigene resulting in exon skipping. We also demonstrated that splicing of ABCA4 has different outcomes depending on transfected cell type. Conclusion: Two intronic variants c.4773+3A>G and c.5461-10T>C, both predicted to affect splicing, are indeed disease-causing mutations due to skipping of exons 33, 34, 39 and 40 of ABCA4 gene. The experimental proof that ABCA4 mutations in STGD patients affect protein function is crucial for their inclusion to future clinical trials; therefore, functional testing of all ABCA4 intronic variants associated with Stargardt disease by minigene technology is desirable.
Introduction
Inherited retinal dystrophies (IRDs) represent a progressive group of conditions affecting the retina. The patients usually have poor peripheral vision, night and/or colour blindness that may advance to legal blindness.
There is a great genetic heterogeneity causing IRDs, and to date, according to the Retinal Information Network, more than 260 genes have been associated with autosomal dominant, autosomal recessive and X-linked IRDs (http://www.sph.uth.tmc.edu/RetNet/) (Meindl et al. 1996; Martinez-Mir et al. 1998; Bowne et al. 2002) . The frequency of IRDs in northern Sweden is 1/2000, which is higher than in other regions of Sweden, and most of the disease-causing mutations are unique for this part of Sweden (Golovleva et al. 2010) . Functional effects of coding mutations, such as missense and nonsense, are easier to explain than effects resulting from mutations in noncoding regions. Recently, two clinically distinct IRDs, Leber congenital amaurosis (LCA) and Stargardt disease, type 1 (STGD1), were described within the same Swedish family (Jonsson et al. 2013) . The STGD1 patients were carriers of two intronic variants, c.4773+3A>G and c.5461-10T>C, in the ATP-binding cassette subfamily A, member 4 gene (ABCA4). Both variants were considered disease causative based on the fact that one of the patients was homozygous for c.5461-10T>C and the other one was compound heterozygous for both variants (Jonsson et al. 2013) . The c.5461-10T>C variant is the third most common variant, present in 7.9% of patients with Stargardt. The mutation has been detected on one allele or on both alleles (presumable compound heterozygous or homozygous). Earlier attempts to demonstrate a functional role for the c.5461-10T>C variant in patients' lymphocytes failed, explained by ABCA4 predominant expression in photoreceptors (Rivera et al. 2000) . Recently, however, defective splicing was observed in fibroblasts (Aukrust et al. 2017 ) and photoreceptor progenitor cells derived from patients with c.5461-10T>C mutation (Sangermano et al. 2016) .
ATP-binding cassette subfamily A, member 4 (ABCA4) c.4773+3A>G is another rare variant described in patients with Stargardt (Duno et al. 2012; Braun et al. 2013; Jonsson et al. 2013 ) and has not been reported in the NHLBI Exome Sequencing Project (ESP; http://evs.gs. washington.edu/EVS).
In this study, we analysed the effect of two intronic variants, c.4773+3A>G and c.5461-10T>C, on the splicing of the ABCA4 gene, in human embryonic kidney cells, HEK293T, and in human retinal pigment epithelium cells, ARPE-19, using a minigene system.
Materials and Methods

Patients
We recently described a family with two retinal diseases, LCA and STGD1 (Jonsson et al. 2013) . In two STGD1 patients (III:4 and IV:1, Fig. 1 ), two intronic variants were detected in ABCA4 gene. DNA samples from these patients were available for this study. The study was approved by the Ume a Regional Ethical Review Board. Clinical evaluation of the patients has been reported previously (Jonsson et al. 2013 ).
ABCA4 minigene constructs
For PCR amplification, genomic DNA from compound heterozygote (III:4), the carrier of variants c.4773+3A>G and c.5461-10T>C in ABCA4 gene (NM_000350.2) was used as template. All forward PCR primers contained EcoRI sites, and reverse primers contained NotI sites to enable cloning into the pSPL3 exon-trapping vector. Sequences of all PCR primers are shown in Table 1 . All PCR amplifications were performed using standard conditions. Amplified fragments were cloned into the EcoRI-NotI sites of the pSPL3 exontrapping vector (Invitrogen, Carlsbad, CA, USA), via a pGEM-T Easy Vector (Promega, Madison, WI, USA).
Plasmids containing inserts were analysed by Sanger sequencing to identify wild-type (wt) and mutant (mt) constructs and to rule out any sequence deviations generated by PCR.
For the c.4773+3A>G variant, the construct contained two exons, 33 and 34 ( Fig. 2A) . For the c.5461-10T>C variant, two different constructs were generated: one with only exon 39 and one with both exons 39 and 40 (Fig. 3A) . Due to numerous PCR mismatches revealed by sequencing of c.5461-10C fragment cloned into pGEM-T Easy vector, we introduced the c.5461-10T>C mutation using QuickChange Site-Directed Mutagenesis kit (Agilent Technologies, Santa Clara, CA, USA) with the following primers: 5 0 -CCAACAGTCCTACTTCC CTGTTTCAGACGC and 5 0 -CGCA-GACTTTGTCCCTTCATCCTGACA ACC. (Desmet et al. 2009 ), MaxEnt (Yeo & Burge 2004) and NNSplice as a part of Berkley Drosophila Genome Project (BDGP) (Reese et al. 1997) were used for analysis of spliced products.
Results
Prediction of the c.4773+3A>G and c.5461-10T>C variants on splicing To investigate whether the two ABCA4 intronic variants associated with Stargardt disease affect the splicing of the gene, we first performed in silico analysis. The effect of noncanonical splice-site variants was assessed by the algorithms included in ALAMUT VISUAL software version 2.9 (Interactive Biosoftware). The c.4773+3A>G variant in intron 33 of the ABCA4 gene was predicted to change the donor site at a risk of 58.1% by MaxEnt (Yeo & Burge 2004) , 68.6% risk by NNSplice (Reese et al. 1997 ) and 12.8% risk by HSF (Desmet et al. 2009 ), giving an average risk prediction of aberrant splicing of 46.5% (Table 2 ). The c.5461-10T>C variant in intron 38 of the ABCA4 gene was predicted to change the acceptor site at a risk of 5.9% by MaxEnt, 6.4% by NNSplice and 0.8% by HSF, giving an average risk prediction of aberrant splicing of 4.4% (Table 2 ).
In vitro splice assay using ABCA4 minigenes with the c.4773+3A>G variant To analyse whether the ABCA4 c.4773+3A>G variant had any effect on splicing, wt and mutant (mt) ABCA4 minigenes were generated ( Fig. 2A) . The minigenes were transfected twice into HEK293T and once into ARPE-19 cells followed by analysis of splicing products. The wt ABCA4 c.4773+3A minigene transfected into HEK293T cells resulted in two distinct products of 441 and 366 bp, respectively (Fig. 2B ). We could confirm by Sanger sequencing that the 441 bp product corresponded to correct splicing of exons 33 and 34 while the 366 bp fragment was the result of exon 34 skipping ( Fig. 2D ,E). Transfection of the mutant ABCA4 c.4773+3G minigene into HEK293T resulted in four products: 441, 366, 335 and 260 bp (Fig. 2B ). Correct splicing of exons 33 and 34 in the 441 bp fragment was shown by sequencing. The 366 bp fragment was missing exon 34, and the 335 bp transcript was missing exon 33 (the exon closest to the mutation; Fig. 2D ,E). The 260 bp fragment was the most prevalent and presented skipping of exons 33 and 34.
Transfection of the ARPE-19 cells with wt ABCA4 (c.4773+3A) minigene resulted in three products: very weak 441, 366 and 260 bp (Fig. 2C) . When the mt ABCA4 c.4773+3G minigene was transfected into ARPE-19, the major product represented skipping of both the 33 and 34 exons (Fig. 2C,D) . Thus, ABCA4 exon skipping was observed in both human embryonic kidney HEK293T and human retinal pigment epithelium ARPE-19 cells when the c.4773+3G variant was introduced.
In vitro splice assay using ABCA4 minigenes carrying the c.5461-10T>C variant Two minigene constructs were generated to study the effect of the ABCA4 c.5461-10C variant on splicing. R1 contained only exon 39, with flanking intron sequences, while R2 contained both exon 39 and 40, with flanking intron sequences (Fig. 3A) . When HEK293T cells were transfected with the wt R1 ABCA4 c.5461-10T minigene, the majority of the transcripts were correctly spliced, represented by the 384 bp fragment. A weak 260 bp fragment corresponding to exon 39 skipping was also detected (Fig. 3B) . For the mt R1 ABCA4 c.5461-10C minigene, only the 260 bp product was generated, indicating complete skipping of exon 39 (Fig. 3B) . HEK293T cells transfected with the wt R2 ABCA4 c.5461-10T minigene showed only correctly spliced transcript. The mt R2 ABCA4 c.5461-10C minigene resulted in two bands, corresponding to transcripts with skipped exon 39 (390 bp) or loss of exons, 39 and 40 (260 bp; Fig. 3B ,E). We also transfected ARPE-19 cells with the wt R1 ABCA4 (c.5461-10T) minigene yielding three splicing products where the most distinct band corresponded to a transcript with correctly spliced SDv and acceptor site of exon 39 but with inclusion of 116 bp of pSPL3 vector at the donor site of exon 39 (500 bp; Fig. 3C, Fig. S1 ). The inclusion of 116 bp of pSPL3 vector sequence in wt R1 transfected into ARPE-19 cells can be explained by existence of a noncanonical potential acceptor site (actctgtgttagTT) scoring 73.47 by HSF (0-100) and 5.43 by MaxEnt (À20 to +20) and a donor site (GAGtgaagg) scoring 96.31 by HSF and 10.28 by MaxEnt in the pSPL3 vector where the sequence retention occured (Fig. S1C) . The second and third band corresponded to correctly spliced transcript (384 bp) and with skipped exon 39 (260 bp; Fig. 3C,D) . When the mt R1 ABCA4 c.5461-10C was transfected into ARPE-19, only the product with exon 39 skipping was observed (Fig. 3C,D (Lewis et al. 1999; Webster et al. 2001; Downs et al. 2007; Cideciyan et al. 2009; Schindler et al. 2010) . It is not a rare event that ABCA4 testing reveals only one mutation in STGD cases with recessive inheritance pattern when all 50 coding exons have been analysed (Zernant et al. 2014; Bax et al. 2015) . Fortunately, the number of resolved cases is increasing due to the discovery of deep intronic variants by next-generation . ABCA4 exons (purple) and flanking introns (grey) were cloned into the pSPL3 vector (black) with a wild-type (wt) or mutant (mt) c.4773+3A>G donor site between two pSPL3 exons (yellow); splice donor vector (SDv) and splice acceptor vector (SAv). Positions of SD6 and SA2 primers for splice analysis are displayed. HEK293T cells and ARPE-19 cells were transfected with wt or mt ABCA4 minigene or an empty pSPL3 vector. Transfection into HEK293T was performed twice and into ARPE-19 cells once. After RNA extraction and cDNA synthesis, splicing products were amplified by PCR using SD6 and SA2 vector-specific primers and visualized by agarose gel electrophoresis. Resolution of splicing PCR products derived from HEK293T is shown in (B) and from ARPE-19 in (C). In the control pSPL3, only SDv -SAv splicing occurred, resulting in a 260 bp product. In HEK293T cells, wt minigene had both expected splicing (441 bp) and skipping of exon 34 (366 bp). Mt minigene resulted in expected splicing (441 bp), skipping of exon 34 (366 bp), skipping of exon 33 (335 bp) and skipping of both exons 33 and 34 (260 bp). In ARPE-19 cells, the wt hybrid minigene appears to have very little of expected splicing product while mt minigene resulted in complete skipping of both exons (C). Splicing products are schematically presented in (D). Sanger sequencing (E) confirmed splicing of exon 33 and exon 34 (E, upper panel), skipping of exon 34 (E, middle panel) and skipping of exon 33 (E, lower panel).
sequencing (Braun et al. 2013; Zernant et al. 2014; Bauwens et al. 2015; Bax et al. 2015) . Moreover, majority of reported sequence variants are rare, and their pathogenicity is based only on bioinformatic prediction which is limited for variants outside coding regions (Webster et al. 2001; Schindler et al. 2010; Zernant et al. 2011 ). Prediction of the functional impact is straightforward for frameshift mutations, stop mutations and canonical splice-site mutations resulting in truncation of protein but is more difficult for variants outside the conserved sequences at exon-intron junctions with an unclear functional effect.
An intronic ABCA4 variant c.5461-10T>C was first described in STGD patients in 1999, and an effect on splicing was considered as the result of this DNA change. Earlier attempts to show aberrant splicing of the ABCA4 transcript, using COS7 cells or patient-derived lymphoblastoid cells, failed (Maugeri et al. 1999; Fig. 3 . Exon skipping as a result of ATP-binding cassette subfamily A, member 4 (ABCA4) c.5461-10T>C mutation. A schematic illustration of the pSPL3-ABCA4 c.5461-10T>C minigenes R1 and R2 (A). ABCA4 exons (purple) and flanking introns (grey) were cloned into the pSPL3 vector (black) with a wild-type (wt) or mutant (MT) c.5461-10T>C donor site between two pSPL3 exons (yellow); splice donor vector (SDv) and splice acceptor vector (SAv). Positions of SD6 and SA2 primers for analysis of splice products are displayed. R1 minigene contained only exon 39 of ABCA4 while exons 39 and 40 were present in minigene R2. Transfection of HEK293T and ARPE-19 cells was performed in biological duplicates with either wt or mt ABCA4 minigene and an empty pSPL3 vector. After RNA extraction and cDNA synthesis, splicing products were amplified by PCR using SD6 and SA2 vector-specific primers and visualized by agarose gel electrophoresis. Resolution of splicing PCR products derived from HEK293T is shown in (B) and from ARPE-19 in (C). Transfection of HEK293T cells with wt minigene R1 resulted in two splicing products, one with expected size, 384 bp, and another one from only pSPL3, 260 bp. Transfection with the mt minigene R1 led to complete skipping of exon 39 demonstrating only 260 bp fragment. Only one splicing product of expected size, 514 bp, was revealed in mRNA from HEK293T cells transfected with wt minigene R2. Transfection with mt minigene R2 resulted in products with skipping of either exon 39 (390 bp) or both of them (260 bp). Exon 39 skipping was confirmed by sequencing of PCR products (E, upper and lower panels). In ARPE-19 cells (C), the wt R1 produced three products, one with inclusion of 116 bp of pSPL3 in addition to exon 39 (500 bp), one with expected size 384 bp and the third corresponding to pSPL3 at 260 bp. Transfection with mt minigene R1 resulted in skipping of exon 39 (260 bp). The wt minigene R2 transfected into ARPE-19 produced two products, the most distinct band being correctly splicing of exon 39 and 40 (514 bp) and the weaker band being skipping of both exons (260 bp). The mt minigene R2 resulted in three bands and sequencing revealed wt splicing of exon 39 and 40 (514 bp), skipped exon 39 (390 bp) and skipping of both exon 39 and exon 40 (260 bp) (C). Splicing products are schematically presented in (D). Rivera et al. 2000) . The variant was therefore believed to exist in linkage disequilibrium with a pathogenic variant (Maugeri et al. 1999; Rivera et al. 2000; Klevering et al. 2005) . Since then, the c.5461-10T>C has been described as the third most frequent gene variant associated with STGD1 (Zernant et al. 2011; Roberts et al. 2012; Miraldi Utz et al. 2014 ) and referred as a relatively severe allele (Cideciyan et al. 2009; Schindler et al. 2010; Roberts et al. 2012) . Recently, the molecular mechanism of this disease-causing variant was finally solved by demonstration of aberrant splicing of the ABCA4 transcript (Sangermano et al. 2016; Aukrust et al. 2017) . Skipping of exon 39 or both exons 39 and 40 was observed in induced pluripotent stem cells (iPSC) differentiated to photoreceptor progenitor cells (PPCs) using fibroblasts from a STGD patient with c.5461-10T>C mutation (Sangermano et al. 2016) .
In this study, we could show some skipping of exon 39 in HEK293T transfected with the wt minigene containing only exon 39, while no exon skipping was observed using the wt construct with both exons 39 and 40. In contrast, exon 39 was completely lost when HEK293T cells were transfected with the mutant exon 39 construct. A mix of splicing products, with skipped exon 39, or both exons 39 and 40 was detected with the mutant minigene containing both exons, with the majority of the transcripts lacking both exons. A transcript lacking exon 39 and/or exon 40 was also detected in the RNA isolated from patients' cultured fibroblasts followed by RT-PCR (Aukrust et al. 2017) . The loss of exon 39 would result in a frameshift and premature stop, p.Thr1821Valfs*13. The failure to show the c.5461-10T>C effect on splicing using a ABCA4 minigene construct in COS7 cells might be explained by shorter intron sequences flanking the exon 39 (Rivera et al. 2000) compare to at least 180 bp of flanking sequences used in our minigene constructs. In our previous study (Jonsson et al. 2013) , we also failed to observe alternative splicing in lymphocytes from peripheral blood from the homozygous c.5461-10T patient (IV:1, Fig. 1 ). The possibility of other factors affecting the strength of splice acceptor site of the exon 39 or sequence changes in predicted branch site could not be ruled out (Sangermano et al. 2016) . Presence of additional splicing products with loss of exon 40 or both exons 39 and 40 reported in other studies was proposed to be a result of a possible exploration of any of three alternative donor sites of exon 39 (Sangermano et al. 2016) . Moreover, a part of pSPL3 vector sequence was included in the mRNA for the wt construct R1 ABCA4-10T in ARPE-19 cells, but not in HEK293T. Splice analysis by HSF revealed both cryptic acceptor and donor sites at these positions in the pSPL3 vector (Figs S1, S2).
Another intronic variant ABCA4, the c.4773+3A>G, also analysed in this study represents a rare sequence change reported in three cases (Duno et al. 2012; Braun et al. 2013; Jonsson et al. 2013 (Shapiro & Senapathy 1987) (Fig. S2 ). An earlier study analysed the splice-site consensus in 30 cases of disease-associated A>G mutations at the +3 position of 5 0 splice sites (5 0 ss) (Madsen et al. 2006) . They found that all cases harboured nonconsensus wt splice-site sequences, especially at positions +4 and +5, making them naturally weaker and having suboptimal base pairing to U1 small nuclear RNA (U1) (Madsen et al. 2006 ), shown to be required for recognition of splice donor sites and initiation of the splicing process (Wahl et al. 2009 ). Thus, A>G transition at +3 weakens the base pairing to U1, making these substitutions likely pathogenic. Another study indicates likewise, showing that a G at +3 is less tolerated if there is nonconsensus at either +4 (C, G, T) or +5 (A, C, T) (Roca et al. 2008 ). The 5 0 ss of exon 33 in ABCA4 has a nonconsensus sequence (GGG|GTATGT) at +4 compared to consensus for U1 snRNA 5 0 ss (CAG|GTAAGT) (Roca et al. 2008) which is in concordance to the previous studies and corroborate with our results.
For wt ABCA4+3A>G, different splice events happened in the human embryonic kidney HEK293T cells compared to the human retinal pigment epithelium ARPE-19 cells when transfected with the same minigene. The exon 34 was skipped almost completely in ARPE-19 and only partially in HEK293T cells. When analysing the splice junctions of exon 34 with HSF (Desmet et al. 2009 ), MaxEnt (Yeo & Burge 2004) and NNSplice (Reese et al. 1997 ), we could see that exon 34 is more weakly defined compared to neighbouring exons (Table S1 ).
The discrepancies in splicing patterns between HEK293T and ARPE-19 cells upon transfection of wt ABCA4 (c.4773+3A) and wt R1 ABCA4 (c.5461-10T) could be explained by possible abundance or sensitivity of splicing factors in ARPE-19 compared to HEK293T. These differences in splicing highlight the importance of cell type chosen for in vitro splice assays and pointing towards speciesspecific and/or cell type-specific differences in the splicing machineries (Garanto et al. 2015) . During recent years, important progress has been made using gene therapy for IRDs treatment. One of the methods is antisense oligonucleotide (AONs) targeting the mutated premRNAs and rendering them for degradation. Therapeutics with AONs has also been promising for splice mutations by blocking the recognition sequence of aberrant splice sites. It has been shown that AONs restore wt splicing in lymphoblastoid cells from LCA patients with an intronic variant in the CEP290 gene resulting in an inclusion of an aberrant exon to the CEP290 mRNA transcript (den Hollander et al. 2006; Collin et al. 2012) . Another approach to IRDs treatment caused by splice mutation is exploration of the mutated U1 small nuclear RNA (U1). The retinitis pigmentosa phenotype caused by RPGR c.1245+3 variant resulting in skipping of exon 10 was partially rescued by altering U1 to have full complementarity over the mutated RPGR sequence in patientderived fibroblast cells (Glaus et al. 2011) . This later treatment approach would be suitable to access the ABCA4 c.4773+3A>G mutation investigated in this study as it destroys the splice donor recognition site and causes exon skipping.
In conclusion, we provide functional evidence that two intronic variants c.4773+3A>G and c.5461-10T>C, both predicted to affect splicing, result in skipping of exons 33, 34, 39 and 40 and therefore interpreted as pathogenic variants in accordance with standards and guidelines for the interpretation of sequence variants (Richards et al. 2015) . The experimental proof that ABCA4 mutations in STGD patients affect protein function is crucial for their inclusion to future clinical trials. This information is also valuable for genetic counselling of the families with intronic mutations present. For the same purpose, functional testing of all ABCA4 intronic variants associated with Stargardt disease is desirable.
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